Accepted at 6:44 p.m. Jan, 12, 2025 by Eli.Tanenbaum
Bulk Suggestion Bulk ID: Eli.Tanenbaum/01.12.25-06:55AM
Author: Eli.Tanenbaum
Related Note: 1497203185934
Rationale for change

changing formerly immune thrombocytopenic purpura to idiopathic thrombocytopenic purpura

Extra Extra
Text
Rituximab is indicated for {{c1::immune thrombocytopenia (ITP)}} and {{c1::thrombotic thrombocytopenic}} purpura
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy


Watch Monoclonal Antibody Therapy




Watch Quantitative Platelet Disorders
Sketchy 2
Empty field
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize



Review Immune Thrombocytopenic Purpura (ITP)
Physeo
Empty field
Bootcamp
Watch associated Bootcamp video - Platelets: Platelet Disorders

Watch associated Bootcamp video - Cellular Injury and Neoplasia: Cell Cycle Independent Drug Targets
OME

Additional Resources
Empty field
One by one
Empty field
#AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::06_Platelets::04_Thrombotic_Microangiopathies #AK_Step1_v12::#OME::PreClinical::Immunology !AK_UpdateTags::AnKing_Image::!Subjects::Hematology::Platelet_disorders #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::05_Pharm::18_Anticancer_monoclonal_antibodies::*Rituximab::Rituximab #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::06_Platelets::03_Platelet_Disorders #AK_Step1_v12::#Pixorize::03_Pharmacology::12_Oncology_Pharm::19_Rituximab #AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step1_v12::#SketchyPath::09_Blood_&_Coagulation::03_Coagulopathies_&_Platelet_Disorders::01_Quantitative_Platelet_Disorders !AK_UpdateTags::Step1decks::Zanki-Pharmacology #AK_Step1_v12::^Other::^HighYield::1-HighYield #AK_Step1_v12::#Pixorize::01_Biochemistry::18_Platelet_Disorders::05_Immune_Thrombocytopenic_Purpura_(ITP) #AK_Step1_v12::#Bootcamp::Pathology::02_Cellular_Injury_&_Neoplasia::11_Cell_Cycle_Independent_Drug_Targets #AK_Step1_v12::^Other::^EXPN #AK_Step1_v12::#B&B::11_Hematology::04_Cancer_Drugs::06_Other_Cancer_Drugs::Extra #AK_Step1_v12::#SketchyPharm::08_Antineoplastics::03_Kinase_Inhibitors_&_Monoclonal_Antibodies::02_Monoclonal_Antibody_Therapy::zanki_extra #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::04_Pathology::17_Platelet_disorders::*Immune_Thrombocytopenic_Purpura #AK_Step1_v12::#FirstAid::02_Immunology::04_Immunosuppressants::03_Therapeutic_antibodies::01_Autoimmune_disease_therapy::*Rituximab #AK_Step1_v12::#FirstAid::02_Immunology::04_Immunosuppressants::03_Therapeutic_antibodies !AK_UpdateTags::AnKing_Image::Mujeeb::Platelet_disorders #AK_Step2_v12::#B&B::07_Hematology_and_Oncology::02_Coagulation::01_Thrombocytopenia::Extra